In the most up-to-date review, a workforce led by Imperial’s Centre for copyright Investigation analysed fMRI scans of participants from both of these trials, which involved Nearly 60 participants: an open label demo in treatment-resistant despair – where all individuals received psilocybin; plus a randomised Handle demo in additional normal de